Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498004 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3373883 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL7880266 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL498005 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3805806 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL17970111 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL3970772 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL8161544 | 1.00 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL2288077 | 0.96 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4DDB1 | |
| SCHEMBL2291426 | 0.96 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4337/4885ADRA2B 4492/4885ADRA2C 3960/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | ADRB3 4531/4885ADRA2B 4489/4885ADRA2C 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.